Osimertinib for Treating Locally Advanced or Metastatic EGFR T790M Mutation-Positive Non-Small-Cell Lung Cancer (TA416)

Technology Appraisal Guidance No. 416

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Osimertinib is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only:

  • after first-line treatment with an EGFR tyrosine kinase inhibitor and
  • if the conditions in the managed access agreement for osimertinib are followed.

1.2 This guidance is not intended to affect the position of patients whose treatment with osimertinib was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta416

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

    Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

    Issue Date: October 2016


    Have you registered with us yet?

    Register now to enjoy more articles and free email bulletins

    Register
    Already registered?
    Sign in

    More from MIMS

    Drug shortages - live tracker

    Drug shortages - live tracker

    Use our constantly updated shortages tracker to check...

    Live updates: Coronavirus (COVID-19) in the UK

    Live updates: Coronavirus (COVID-19) in the UK

    Use our timeline to follow the latest coronavirus developments...

    SGLT2 inhibitors summarised in new MIMS table

    SGLT2 inhibitors summarised in new MIMS table

    Prescribers can quickly compare key features and benefits...

    Proposed withdrawal of bipolar disorder treatment revoked

    Proposed withdrawal of bipolar disorder treatment revoked

    The manufacturer of first-line bipolar disorder treatment...